VAS2870, identified by Vasopharm GmbH as a pan-NOX inhibitor, inhibits all NOX isoforms except NOX3 in cellular assays and particularly shows a 40% to 70% inhibition of NOX2 and NOX4, meaning it is suitable for evaluation in AD models [82,83]. Here, NOX4 is linked to Alzheimer disease.